Specialty Societies Increasingly Hold Key To Reimbursement, Insiders Say
This article was originally published in The Gray Sheet
Executive Summary
Physician specialty societies are becoming increasingly influential in device reimbursement decisions, say industry insiders
You may also be interested in...
Uterine Fibroid Treatments Will See Outpatient Payment Boost In 2008
Reimbursement for uterine fibroid treatments get a boost in CMS' 2008 hospital outpatient 1rule, fueling industry expectations for increased market penetration by device-based alternatives to surgery
Professional Societies Collaborate On New Carotid Stent Coverage Request
A coalition of professional societies is preparing to ask CMS to reconsider its national Medicare coverage policy on carotid stents and agree to cover the entire FDA-approved indication for the devices, according to the Society for Cardiovascular Angiography and Intervention
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.